Denmark’s Biotech Sector Best in Europe  

2016.08.29

For the second year running, Denmark’s biotech sector is awarded a global top three ranking by Scientific American Worldview and is praised for its generous public sector investment and speedy drug trial application process.

Denmark takes the global top three spot in the 2016 Scientific American Worldview Scorecard, assessing countries worldwide according to their biotechnology innovation potential, ahead of its European contemporaries.

Denmark gets the top score for intensity, boasting 215.4 international patent applications filed per million inhabitants. When compared to Europe’s four largest economies, Denmark’s productive patent filling puts the country ahead of the UK, France and the Netherlands, second only to Germany.

Competitive conditions

The life science industry in Denmark currently employs more than 40,000 people. Many of these highly skilled employees are located in Medicon Valley, one of Europe’s top three sites for biotech innovation alongside Cambridge in the United Kingdom and Basel in Switzerland. Add to this a generous public sector investment of around 5.6 billion Euros as well as a drug trial application process of approx. 6 weeks and a high approval rate of approx. 95%. These are just some of Denmark’s biotechnology strongholds.

Want to know more about biotech in Denmark?

If you want to know more about Denmark’s biotech industry please contact Rasmus Beedholm-Ebsen, Investment Manager Life Science, via mobile phone +45 8993 5107 or e-mail rasbee@um.dk.

Next step

Explore business cases

Contact

Rasmus Beedholm-Ebsen

Rasmus Beedholm-Ebsen

+45 8993 5107

rasbee@um.dk

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×